The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

被引:13
|
作者
Moon H. [1 ]
Noh W.C. [2 ]
Kim H.-A. [2 ]
Kim E.-K. [2 ]
Park K.W. [3 ]
Lee S.S. [4 ,5 ]
Choi J.H. [1 ]
Han K.W. [1 ]
Byun B.H. [1 ]
Lim I. [1 ]
Kim B.I. [1 ]
Choi C.W. [1 ]
Lim S.M. [1 ]
机构
[1] Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75, Nowon-ro, Nowon-gu, Seoul
[2] Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[3] Department of Radiology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[4] National Radiation Emergency Medical Center, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[5] Department of Pathology, Korea Cancer Center Hospital, Seoul
关键词
Breast cancer; Dual phase; Estrogen receptor; Human epidermal growth factor receptor 2; Positron emission tomography; Retention index;
D O I
10.1007/s13139-016-0412-2
中图分类号
学科分类号
摘要
Purpose: This study investigates the correlation of retention index (RI) using the dual phase FDG PET/CT scan with the breast cancer biomarkers. Methods: A total of 55 patients with breast cancer underwent dual phase FDG PET/CT scans (60 and 120 min after FDG injection) before treatment. SUVmax and SUVmean of the primary breast tumors were measured, then the percent change of SUVmax and SUVmean between the two scans were calculated, and denoted as RImax and RImean, respectively. After the surgical resection of the breast tumor, the status of biomarkers (ER, PR, and HER-2) was evaluated in the postsurgical specimen. Results: RImean was significantly higher in ER (−) (median, 16.2; IQR, 10.8–21.0) or HER-2 (+) (median, 16.1; IQR, 10.7–21.6) tumors than in ER (+) tumors (median, 9.9; IQR, 5.5–15.3) or HER-2 (−) tumors (median, 10.5; IQR, 5.5–16.1). However, there were no significant differences of SUVmax or RImax according to the ER or HER-2 status. There were no significant differences of any PET parameters between PR (+) and PR (−) tumors. Based off ROC curve analyses, RImean predicted the ER (+) tumors (AUC, 0.699; p = 0.006), and HER-2 (+) tumors (AUC, 0.674; p = 0.022), but not the PR (+) tumors. However, neither SUVmax nor RImax predicted ER (+), PR (+), or HER-2 (+) tumors. Conclusions: Retention index of SUVmean can reflect the ER and HER-2 status of breast cancers. Higher retention index of SUVmean might associate with lower ER expression and higher HER-2 expression. © 2016, Korean Society of Nuclear Medicine.
引用
收藏
页码:246 / 254
页数:8
相关论文
共 50 条
  • [21] The Functional Adipose Tissue in 18F-FDG PET/CT in Estrogen Receptor Positive Postmenopausal Breast Carcinoma
    Yilmaz, S. A.
    Akbulut, A.
    Koca, G.
    Korkmaz, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S150 - S150
  • [22] Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer
    Qin Qinghong
    Gao Fangfang
    Jiang Wei
    Tan Qixing
    Mo Qinguo
    Wei Changyuan
    CHINESE MEDICAL JOURNAL, 2014, 127 (18) : 3272 - 3277
  • [23] Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
    Lindstrom, Linda Sofie
    Karlsson, Eva
    Wilking, Ulla M.
    Johansson, Ulla
    Hartman, Johan
    Lidbrink, Elisabet Kerstin
    Hatschek, Thomas
    Skoog, Lambert
    Bergh, Jonas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2601 - 2608
  • [24] Molybdenum Target X-Ray Features and Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 in Invasive Breast Cancer
    Tailaiti, Gulijire
    Maimaiti, Gulanbaier
    Aikeremu, Youlituzi
    Tuerdi, Batuer
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 2777 - 2783
  • [25] Evaluation of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Status Before and After Neoadjuvant Chemotherapy in Breast Cancer Patients
    Verma, Adarsh
    Kar, Amrita Ghosh
    Meena, Ram Niwas
    Patne, S. C. U.
    Mishra, Shashi Prakash
    Khanna, Seema
    Khanna, Rahul
    INDIAN JOURNAL OF SURGERY, 2021, 83 (SUPPL 2) : 399 - 403
  • [26] Evaluation of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Status Before and After Neoadjuvant Chemotherapy in Breast Cancer Patients
    Adarsh Verma
    Amrita Ghosh Kar
    Ram Niwas Meena
    S. C. U. Patne
    Shashi Prakash Mishra
    Seema Khanna
    Rahul Khanna
    Indian Journal of Surgery, 2021, 83 : 399 - 403
  • [27] Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer
    Qin Qinghong
    Gao Fangfang
    Jiang Wei
    Tan Qixing
    Mo Qinguo
    Wei Changyuan
    中华医学杂志(英文版), 2014, (18) : 3272 - 3277
  • [28] Immunoexpression of claudin-4 and correlation with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-neu in breast cancer
    Kumar, Niranjan
    Tandon, Megha
    Chintamani, C. M.
    Saxena, Sunita
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (06) : 1766 - 1770
  • [29] Somatostatin Receptor Imaging with 68Ga-DOTATATE PET/CT and its Comparison with 18F-FDG PET/CT in Patients with Estrogen Receptor Positive Metastatic Breast Cancer
    Chandekar, K.
    Satapathy, S.
    Dharmashaktu, Y.
    Ballal, S.
    Ranjan, P.
    Batra, A.
    Gogia, A.
    Mathur, S.
    Bal, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S484 - S484
  • [30] Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study
    Vohra, Poonam
    Buelow, Benjamin
    Chen, Yunn-Yi
    Serrano, Maria
    Vohra, Manjiv Singh
    Berry, Anna
    Ljung, Britt-Marie
    CANCER CYTOPATHOLOGY, 2016, 124 (11) : 828 - 835